

MedAdVisor Limited
(ACN 145 327 617)
Chairman's Address
to the Annual General Meeting
23 October 2018

Good morning ladies and gentlemen and welcome to this year's Annual General Meeting.

I am joined today by our CEO, Robert Read and my fellow Board members Sandra Hook and Jim Xenos, and Company Secretary, Carlo Campiciano. Executive director and our co-founder Josh Swinnerton is establishing our business platform in the USA and sends his apologies.

I'll say a few words on our work since our last AGM, and how we see the future.

MedAdvisor is focused on innovating to improve the medication journey for patients to enhance how people manage their medication, helping them to be in control and ultimately - healthier.

Domestically

We have increased our services to pharmacies with our PlusOne software, which identifies and books professional services for our pharmacies 7 million+ eligible patients, building revenue for pharmacies and MedAdvisor. More than a third of our pharmacies are already using this new services module.

Over 1,000,000 patients are connected to MedAdvisor, improving their medication management journey,, thus making the platform highly attractive to pharmaceutical manufacturers to connect with their patients – this year we ran a total of 32 PEPs across the MedAdvisor platform.

We are perfectly positioned to help recruit for clinical trials and are now deriving income from this service. Many hundreds of such trials are undertaken in Australia each year by pharma and biotechnology companies, and we can efficiently identify patients reducing the time needed to either start or complete trials. The industry is telling us that for every day delay in a trial being completed there is \$8m in lost revenue. Therefore, MedAdvisor is uniquely placed to help speed up trial recruitment.

We were delighted to welcome leading diversified healthcare group EBOS as a shareholder in 2017 and, working closely with EBOS, we are partnering with three of their subsidiary companies to drive growth, including our initial entry into hospitals.

Our core operational expenditure is funded by our revenue. However, we are a growth company and we are investing strongly in the growth of our business, both domestically and internationally. This will see a step up in our cost base in FY19 to deliver on these opportunities that we are funded to pursue.

International

We have commenced our entry into the US market by partnering with PDX to integrate our software with the leading US dispense software company. PDX are a supportive partner and will co-market our platform to their 10,000 strong pharmacy network – which is almost twice the size of the total Australian market.

We have appointed two new experienced Executives, Jim Rotstart and Luke Merrow to accelerate our US roll out.

Jim is an Executive Vice President of Adheris, a leading firm in the field of prescription compliance management and previously, he held senior positions at two of the largest US retail pharmacy chains. Luke was a co-founder and recent Chief Technology Officer of Eliza Corporation, a healthcare engagement and communication solution provider, and also co-founded Adheris. Their roles are to focus on the launch of the product in the US and to drive engagement with US patient communications companies, health insurers and pharmaceutical companies.

In the UK we have been active with potential customers and expect to commence working with pharmacy chains in the near future.

I thank our outstanding team of committed and talented people who are making a difference to patients' lives. Our executives are constantly forging alliances and seeking opportunities to ensure that MedAdvisor is an integral part of Australian, and then global, healthcare.

Thank you also to each of our shareholders who are helping MedAdvisor become a successful global business, that ultimately helps people be healthier.

Peter Bennetto
Chairman



MedAdvisor Limited

ACN 145 327 617
Level 2
971 Burke Road
Camberwell VIC 3124

phone +61 3 9095 3036
fax: +61 3 9882 3317
email: corporate@medadvisor.com.au
PO Box 8225 Camberwell North VIC 3124

23 October 2018

Company Announcements Office
ASX Limited
Electronic Lodgement System

Results of MedAdvisor Limited [ASX:MDR] – Annual General Meeting

The Directors of MedAdvisor Limited (Company) are pleased to announce that at the Annual General Meeting of Shareholders held today, all resolutions put to the meeting were passed unanimously by a show of hands.

In accordance with Section 251AA (2) of the Corporations Act 2001 and Listing Rule 3.13.2, the Company hereby provides the following information on proxy votes:

Resolution	For	Against	Abstain	Excluded	Total
1. Adoption of Remuneration Report	383,797,231	15,410,837	3,077,860	354,365,126	756,651,054
2. Re-election of Director – Mr J Swinnerton	753,263,511	417,837	2,969,706	-	756,651,054
3. Re-election of Director – Mr J Xenos	753,223,511	457,837	2,969,706	-	756,651,054
4. Approval of 10% Placement Capacity	659,158,038	585,837	96,907,179	-	756,651,054
5. Employee Option Plan	384,702,549	16,543,379	1,040,000	354,365,126	756,651,054
6. Constitution	755,943,217	457,837	50,000	-	756,651,054
7. Takeover Bid Approval	756,273,512	192,542	185,000	-	756,651,054

Yours Sincerely,
Peter Bennetto
Chairman